Human parvovirus B19 infection during pregnancy – Value of modern molecular and serological diagnostics

Enders, Martin; Schalasta, Gunnar; Baisch, Carola; Weidner, Andrea; Pukkila, Laura; Kaikkonen, Leena; Lankinen, Hilkka; Hedman, Lea; Söderlund‐Venermo, Maria; Hedman, Klaus

doi:10.1016/j.jcv.2005.11.002

Cited by 94 publications

(76 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of 120,000 Danish and 140,000 Finnish contemporary blood donors, many had virus type 1 in plasma, but none had type 2 or 3 (13,18). Also, in the sera of symptomatic European patients, the occurrence of virus type 2 has been sporadic (9,(13)(14)(15)(16). Furthermore, in plasmaderived coagulation factor concentrates, type 2 DNA has been detected rarely, yet more often in older preparations (37).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bioportfolio: Lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue

Norja

Hokynar

Aaltonen³

et al. 2006

Proc. Natl. Acad. Sci. U.S.A.

248

216

View full text Add to dashboard Cite

Human erythrovirus is a minute, single-stranded DNA virus causing many diseases, including erythema infectiosum, arthropathy, and fetal death. After primary infection, the viral genomes persist in solid tissues. Besides the prototype, virus type 1, two major variants (virus types 2 and 3) have been identified recently, the clinical significance and epidemiology of which are mostly unknown. We examined 523 samples of skin, synovium, tonsil, or liver (birth year range, 1913-2000), and 1,640 sera, by qualitative and quantitative molecular assays for the DNA of human erythroviruses. Virus types 1 and 2 were found in 132 (25%) and 58 (11%) tissues, respectively. DNA of virus type 1 was found in all age groups, whereas that of type 2 was strictly confined to those subjects born before 1973 (P < 0.001). Correspondingly, the sera from the past two decades contained DNA of type 1 but not type 2 or 3. Our data suggest strongly that the newly identified human erythrovirus type 2 as well as the prototype 1 circulated in Northern and Central Europe in equal frequency, more than half a century ago, whereafter type 2 disappeared from circulation. Type 3 never attained wide occurrence in this area during the past >70 years. The erythrovirus DNA persistence in human tissues is lifelong and represents a source of information about our past, the Bioportfolio, which, at the individual level, provides a registry of one's infectious encounters, and at the population level, a database for epidemiological and phylogenetic analyses.epidemiology ͉ gene therapy ͉ parvovirus ͉ phylogeny ͉ single-stranded DNA

show abstract

Section: Resultsmentioning

confidence: 99%

“…The virus multiplies restrictively in the erythroid precursor cells of the bone marrow (5), giving rise to high-titer viremia, which, according to sensitive techniques, subsides more slowly than thought previously (6)(7)(8)(9)(10). The viral DNA genome was long considered highly stable and the species, phylogenically monolithic (11).…”

mentioning

confidence: 99%

Bioportfolio: Lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue

Norja

Hokynar

Aaltonen³

et al. 2006

Proc. Natl. Acad. Sci. U.S.A.

248

216

View full text Add to dashboard Cite

show abstract

“…8 In Germany, screening of parvovirus B19 antibodies of pregnant women working at schools and day Turkiye Klinikleri J Gynecol Obst 2016;26 (2) care centers are recommended although they do not give a contact history. 24 Some reports suggest seronegative pregnant women to avoid contact with parvovirus B19, but it is not possible to prevent transmission by excluding infected patients from their school and workplaces, because patients can transmit the infection before they are symptomatic of erythema infectiosum. The infectivity of immunocompetent patient is already finished at the time of clinical illness.…”

Section: Clinical Manifestations and Transmission Of Parvovirus B19 Imentioning

confidence: 99%

“…IgM positivity detected at early stages of pregnancy may be due to primary infection before conception. 24 Fetal IgM level can only be used after 22 weeks of gestation, because fetus can produce IgM after that period. 5 For the evidence of the recent infection, parvovirus B19 DNA can be investigated in maternal blood.…”

Section: Parvovirus B19 Infections In Pregnant Women and Neonates: Rementioning

confidence: 99%

“…They suggested that the degree of viremia did not correlate with the clinical outcome. 24 Investigating the parvovirus B19 DNA in fetal serum of cord blood or amniotic fluid by polymerase chain reaction (PCR) method is a valuable method in verification and exclusion of the infection. 3,12,16 It is reported that the sensitivities of IgM evaluation on fetal blood sample and DNA searching by PCR are 29%, and 100%, respectively.…”

Section: Parvovirus B19 Infections In Pregnant Women and Neonates: Rementioning

confidence: 99%

See 1 more Smart Citation